Skip to main content

Table 7 Baseline characteristics of HAM-net-registered patients who had been observed for one year (n = 346)

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

  All patients
(n = 346)
Steroid (S) group
(n = 131)
Steroid-
history (SH) group
(n = 82)
Untreated (U) group (n = 85) Miscella-
neous (M) group
(n = 48)
p value Groups with significant difference c)
Sex: Female 260
(75.1%)
97
(74.0%)
60
(73.2%)
67
(78.8%)
36
(75.0%)
0.832 a)
Age at baseline (year)d 61.8 ± 10.8 62.1 ± 9.30 62.2 ± 11.7 61.5 ± 11.9 60.7 ± 11.0 0.875 b)
Age at onset (year)d 44.6 ± 14.8 47.4 ± 13.6 40.4 ± 15.2 45.0 ± 15.0 43.1 ± 16.0 0.009 b) S > SH
Disease durationd (Time from onset to initial interview) 16.1 ± 11.1 13.9 ± 10.0 20.6 ± 10.8 14.9 ± 11.7 16.7 ± 11.3 < 0.001 b) SH > S, SH > U
Baseline OMDSd 5.7 ± 2.2 5.7 ± 1.9 6.5 ± 2.5 5.0 ± 2.1 5.8 ± 2.2 < 0.001 b) SH > S > U
Rapid progressorse 68 (19.7%) 35 (26.7%) 14 (17.1%) 12 (14.1%) 7
(14.6%)
0.075 a)
  1. Statistical methods: a) By chi-square test, b) By analysis of variance, c) By Tukey post hoc tests
  2. dData are expressed as mean ± standard deviation, e Rapid progressors were defined as those who developed OMDS 5 or above within 2 years from the onset of motor symptoms. Abbrevations: OMDS, Osame motor disability score